Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer

To be part of this study, you would generally need to have been diagnosed with bladder cancer that has grown into the muscle layer (muscle-invasive bladder cancer). The cancer should not have spread to other parts of your body, which doctors call metastatic disease. You must be at least 18 years old, generally fit and well enough to take part, and weigh more than 30 kilograms.

A key requirement is that you will have already completed your initial treatment for bladder cancer, which includes surgery, chemotherapy, and radiotherapy. It's important that you are able to start the study treatment within six weeks after finishing your previous treatments. You will also need to have healthy enough blood counts, kidney function, and liver function.

Your doctors will need to check your medical records, including details of your bladder cancer diagnosis and previous treatments, to ensure you meet all the necessary requirements for the study. There are specific criteria regarding the type of bladder cancer you have, and certain prior treatments that might mean you can't join.

If you decide to take part in this study, you would receive the drug durvalumab after you've finished your initial treatment of surgery, chemotherapy, and radiotherapy. The exact schedule for taking durvalumab and how long you'd be on it would be explained by the study team. You would have regular appointments at the hospital for check-ups, blood tests, and to receive the study drug, which is usually given through a drip.

These appointments are important to monitor your health, see how you're responding to the treatment, and check for any side effects. The study team will tell you how often these visits will be and what tests you'll have. The total duration of your participation in the study, including treatment and follow-up, will be clearly outlined by the researchers.